PROT3EcT, engineered Escherichia coli for the targeted delivery of therapeutics.

Saved in:
Bibliographic Details
Title: PROT3EcT, engineered Escherichia coli for the targeted delivery of therapeutics.
Authors: González-Prieto C; Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA., Lynch JP; Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA., Lesser CF; Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Ragon Institute of Harvard and MIT, Cambridge, MA 02139, USA. Electronic address: clesser@mgh.harvard.edu.
Source: Trends in molecular medicine [Trends Mol Med] 2023 Nov; Vol. 29 (11), pp. 968-969. Date of Electronic Publication: 2023 Aug 11.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 100966035 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-499X (Electronic) Linking ISSN: 14714914 NLM ISO Abbreviation: Trends Mol Med Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1471-499X
DOI:10.1016/j.molmed.2023.07.007